|
Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation |
Wex J, Sidhu M, Odeyemi I, Abou-Setta AM, Retsa P, Tombal B |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Wex J, Sidhu M, Odeyemi I, Abou-Setta AM, Retsa P, Tombal B. Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation. ClinicoEconomics and Outcomes Research 2013; 5: 257-269 Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Agents, Hormonal; Cost-Benefit Analysis; Drug Administration Schedule; Europe; Humans; Leuprolide; Prostatic Neoplasms AccessionNumber 22013027437 Date bibliographic record published 26/07/2013 |
|
|
|